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Abstract
Background: The aims of this study were to investigate the immunolocalization of ezrin and its relationship with
the podoplanin expression in keratocystic odontogenic tumors.
Material and Methods: The immunohistochemical expressions of ezrin and podoplanin by odontogenic epithelium
were evaluated in keratocystic odontogenic tumors using monoclonal antibodies.
Results: Our results showed strong cytoplasmic ezrin and membranous podoplanin expressions in basal epithelial layer
of all keratocystic odontogenic tumors. The cytoplasmic and membranous ezrin expressions were also detected in
suprabasal epithelial layers of tumors. Statistically significant difference between cellular immunolocalization of ezrin
and podoplanin odontogenic epithelium were found by Wilcoxon’s test (p < 0.05). No correlation between both
proteins in keratocystic odontogenic tumors was detected by Spearman test.
Conclusions: These results suggest that ezrin and podoplanin may contribute to the expansive growth and local
invasiveness of keratocystic odontogenic tumors. Additionally, as both proteins were overexpressed by odontogenic
epithelium, their possible roles need to be further explored in benign odontogenic tumors.
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Background
Podoplanin expression has been detected in epithelial
cells of developing tooth germ [1,2] and in odontogenic
epithelium of benign tumors [3-10].
The presence of podoplanin in human tooth germ tis-
sues, adult teeth and cystic odontogenic lesions suggested
that this protein probably is involved in mechanisms of cell
adhesion, epithelial-mesenchymal transition and invasion,
and expansive growth of cystic odontogenic lesions [5].
Previous studies conducted in our laboratory investigated
the association of podoplanin with cellular proliferative ac-
tivity, determined by Ki-67 antibody, in ameloblastomas
[7] and keratocystic odontogenic tumors [9]. We did not
find a statistically significant correlation in ameloblasto-
mas, however this association was observed in keratocystic
odontogenic tumors. Moreover, both podoplanin and
Ki-67 expressions were stronger and co-localized in
keratocystic odontogenic tumors when compared to the
orthokeratinized odontogenic cysts, an indolent lesion.
These fingings suggested that podoplanin positive cells are
located in the cell proliferation centre indicating a role for
this protein in the process of tumoral invasion [9].
Furthermore, Friedrich et al. [8] showed that podopla-
nin expression pattern is similar between keratocyst
odontogenic tumor diagnosed in sporadic and in nevoid
basal cell carcinoma syndrome and, the authors rein-
forced the probable association of this protein with inva-
sion and local recurrences of the tumor.
Recent findings prove that podoplanin is important to
drive directional cell migration in epithelial and tumor
cells [11]. Then, the ability of podoplanin to remodel
cytoskeleton and form filipodia-like membrane extension
[12] has been suggested as important factor in movement
of odontogenic epithelial cells [6]. This podoplanin-
induced cell motility through of actin cytoskeleton re-
arrangement seems to be dependent on the interaction
with the cytoplasmatic ezrin [13], a member of ERM (ezrin,
radixin, moesin) protein family protein [14,15].
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The currently study was designed to analyze the im-
munolocalization of ezrin and its relationship with podo-
planin expression in keratocystic odontogenic tumors.
To the best of our knowledge, this is the first report of
ezrin immunostaining in an odontogenic tumor.
Methods
Patients and tumor samples
All surgical specimens of keratocystic odontogenic tumor
analyzed in this study were obtained from the Laboratory
of Pathology, Bauru School of Dentistry, University of São
Paulo, between 2002 and 2010. The inclusion criteria were:
i) patients with diagnosis of keratocystic odontogenic
tumor based on the classification of the World Health
Organization [16], determined by the sum of the clinical,
radiographic, and microscopic data; ii) availability of the
paraffin block with sufficient and representative amount of
odontogenic tumor for microscopic analysis. Applying the
inclusion criteria, 18 keratocystic odontogenic tumors were
selected for investigation of podoplanin and ezrin immu-
nostaining. This study was approved by the Research
Ethics Committee of the Bauru School of Dentistry,
University of São Paulo (process #85612/2012).
Immunohistochemistry
Formalin-fixed 3 μm sections of keratocystic odonto-
genic tumors were obtained from the pathology archive
for immunohistochemistry analysis of the ezrin and
podoplanin expressions by odontogenic epithelium. After
antigen retrieval using 10 mM citrate buffer, pH 6.0, in a
domestic pressure cooker (model Eterna 4½ L; Nigro,
Araraquara, Brazil) for 4 min, endogenous peroxidase ac-
tivity was blocked by incubation in 3% H2O2 for 20 min.
Each section was incubated overnight at 48°C with
the primary monoclonal anti-podoplanin antibody (D2-40
clone, code#3619-1; Dako North America, Inc., Carpinteria,
CA, USA), dilution 1:200 or anti-ezrin antibody (Dako
North America, Inc., CA, USA), dilution 1:1000, in
phosphate-buffered saline (PBS) with bovine serum
albumin (cat. #A2153, Sigma-Aldrich, St Louis, MO, USA)
solution to block a non-specific reaction. Then, each sec-
tion was incubated with Advance HRP Link System
(cat.#4067, Dako North America, Carpinteria, CA, USA)
for 30 min at 37°C. Both antibodies were detected using
3.30-diaminobenzedine tetrahydrochloride(DAB, cat. #D-
5637, Sigma-Aldrich, St. Louis, MO, USA). Tumor
sections were counterstained with Mayer’s hematoxylin be-
fore being dehydrated and cover slipped. Palatine tonsils
and intestine were used as positive control for podoplanin
and ezrin, respectively. For a negative control, the primary
antibody was omitted during the immunohistochemical
staining. The ezrin and podoplanin expressions by odonto-
genic epithelium of the 18 keratocystic odontogenic tu-
mors were evaluated in ten microscopic fields digitally
captured using an Axiocam camera (Axiocam MR3; Zeiss,
Jena, Germany) attached to a light microscope and re-
corded by Axiovision software (Axiovision 4.7; Zeiss).
A score for ezrin and podoplanin immunostainings
expressed by odontogenic epithelium was based on:
a) the intensity of the immunostaining in the epithelial
odontogenic cells (0 = absent, 1 = weak, 2 = moderate,
3 = strong, and 4 = very strong) and (b) the percentage of
positive odontogenic cells (0 = 0% positive cells, 1 = <25%
positive cells, 2 = 25–50% positive cells, 3 = 50–75% posi-
tive cells, and 4 = >75% positive cells). The final immuno-
staining score was determined by the sum of (a) + (b). Final
scores ranged from 0 to 8 (0 = absent, 1–4 = weak, and 5–
8 = strong). The difference and the correlation between
membranous or cytoplasmic expression of ezrin and podo-
planin expressed in keratocystic odontogenic tumors were
determined by Wilcoxon’s test and Spearman’s correlation
coefficient, respectively. The level of significance was set at
5% for all tests.
Results
Clinical features
Our sample consisted in sixteen patients diagnosed with
keratocystic odontogenic tumors (nine of them were
women and seven men). Patient’s age ranged from 9 to
68 years old (mean 28 years) and they were predomin-
antly white (75%). Most of the tumors were located at
posterior region of the mandible (62.5%), followed by
maxilla (25%), and in 3 cases the localization was not
specified by the surgeon. From the total of 16 patients
with keratocystic odontogenic tumors, 4 of them had
Gorlin-Goltz syndrome and from these, 2 had multiple
lesions but in different locals and periods.
Podoplanin expression by keratocystic odontogenic tumors
The basal layer of the normal oral mucosa presented
positivity for membranous podoplanin as well as the
lymphatic vessels in the subjacent connective tissue,
confirming the integrity of the immunohistochemical re-
action. The membranous and cytoplasmic expression of
podoplanin was intensively concentrated at the basal
layer of the epithelium in all keratocystic odontogenic
tumors (Table 1). The upper layers of epithelium were
negative for this protein (Figure 1) and peripheral cells
of daughter cysts strongly expressed this protein.
Ezrin expression by keratocystic odontogenic tumors
Ezrin was strongly expressed in the cytoplasmic mem-
brane of the spinous layer of normal oral mucosa. Most
of keratocyst odontogenic tumors epithelial cells (83.33%
of cases) strongly expressed cytoplasmic ezrin (Table 2).
The cytoplasmic ezrin was frequently detected in epithe-
lial basal layer and higher membranous ezrin positivity
could be noted in supra-basal layers of epithelium. The
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absent or weak membranous ezrin expression by epithelial
cells was observed in approximately 61% of the tumors.
The odontogenic epithelial cells of daughter cysts also
showed cytoplasmic and membranous ezrin (Figure 2).
Relationship between ezrin and podoplanin expressions
in keratocystic odontogenic tumors
The Wilcoxon’s test was used to compare the subcellular
expression of ezrin and podoplanin in benign odonto-
genic tumors. The differences among membranous ezrin
and membranous (p = 0.003) or cytoplasmic (p = 0.003)
podoplanin expressions were statistically significant
(Table 3). Furthermore, there were no statistically signifi-
cant differences between cytoplasmic ezrin and membran-
ous (p = 0.109) or cytoplasmic (p = 0.201) podoplanin
expressions, as llustrated in Table 3. The Spearman test did
not demonstrate statistically significant correlation be-
tween membranous or cytoplasmic podoplanin and ezrin
expressions in keratocystic odontogenic tumors (Table 4).
Discussion
In recent years, the interest in podoplanin expression in
benign odontogenic tumors has considerably increased
[3,4,6-10,17]. It has been suggested that this protein par-
ticipates in the movement of odontogenic epithelial cells
through actin cytoskeleton rearrangement [6,9]. Although
the odontogenic cell motility induced by podoplanin may
be dependent on its interaction with the activated ezrin,
the connection between both proteins has not previously
been studied in odontogenic tumors.
Our results regarding the immunolocalization of podo-
planin showed strong membranous and cytoplasmic ex-
pressions of the protein detected mainly in the basal layer
of the odontogenic epithelium, even in daughter cysts. In
normal oral mucosa, podoplanin expression was membran-
ous and concentrated at the basal epithelial layer. Our find-
ings corroborated those of previous authors’ [4,8-10,17].
Since Okamoto et al [4] proposed, for the first time, a
possible role of the podoplanin in tumor invasiveness of
Table 1 Membranous and cytoplasmic podoplanin
expression in 18 keratocystic odontogenic tumors
PODOPLANIN
Membranous Cytoplasmic p*
N % N %
Absent 0 0 0 0 1.000
Weak 0 0 1 5.56
Strong 18 100 17 94.44
TOTAL 18 100 18 100
Bauru School of Dentistry – University of São Paulo, São Paulo, 2002 to 2010.
*Wilcoxon test; ρ = statistical significance level of 0.05.
Figure 1 Expression of podoplanin in keratocystic odontogenic tumor. Positivity restricted to the basal layer (IHQ, 400×).
Table 2 Membranous and cytoplasmic ezrin expression in
18 keratocystic odontogenic tumors
EZRIN
Membranous Cytoplasmic p*
N % N %
Absent 10 55.56 2 11.11 0.007
Weak 1 5.56 1 5.56
Strong 7 38.88 15 83.33
TOTAL 18 100 18 100
Bauru School of Dentistry – University of São Paulo, São Paulo, 2002 to 2010.
*Wilcoxon test; ρ = statistical significance level of 0.05.
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keratocystic odontogenic tumors, further investigations
have been conducted in order to understand the exact
function of this protein in the pathogenesis and growth of
these benign tumors [5,8-10,17]. Tsuneki et al. [17] verified
that podoplanin positive cells are located in the cellular
proliferative center of keratocystic odontogenic tumors
suggesting that this protein acts as one of the key regula-
tors in the proliferative process of this tumor. Similarly, the
participation of podoplanin in local invasion of odonto-
genic tumors was reinforced by our previous findings [9].
We have demonstrated the correlation between the podo-
planin expression and the cellular proliferation index in
keratocystic odontogenic tumors [9]. Furthermore, an
interesting study of Zhang et al [10] showed that in kerato-
cystic odontogenic tumors, conservatively treated by de-
compression, there was a significant loss or reduction of
podoplanin expression in the odontogenic epithelium. In
radicular and folicullar cysts, Zustin et al [5] found podo-
planin expression more homogenous, diffused at cytoplasm
and membrane, in epithelial basal and parabasal layer. As
podoplanin is correlated with other proteins involved in
cell proliferation and tumor invasion [9,17], its downregu-
lation may be due to limited activity of the odontogenic
epithelium after the surgical approach [10].
Despite the fact that the exact function of podoplanin
in odontogenic tumors is poorly understood and largely
unknown, the results of the present study taken together
with our previous investigation [9] and those of others
authors [5,17,8,10] strongly suggest that this protein is
involved in local invasion and in the expansive growth of
keratocystic odontogenic tumors, probably orchestrating
the odontogenic epithelial cytoskeleton activity.
A possible mechanism suggested is that podoplanin binds
ezrin and, as a downstream, follows the phosphorylation of
Figure 2 Expression of ezrin in keratocystic odontogenic tumor. Note cytoplasmic positivity in basal and supra-basal layers and membranous
expression in the most superficial level of the odontogenic epithelium (IHQ, 400×).
Table 3 Comparison between membranous and cytoplasmic podoplanin and ezrin expression in 18 keratocystic
odontogenic tumors
Podoplanin Ezrin
M (%) C (%) M (%) C (%) M PO M PO C PO C PO
X X X X
M EZ C EZ M EZ C EZ
Absent 0 0 55.56 11.11 p = 0.003 p = 0.109 p = 0.003 p = 0.201
Weak 0 5.56 5.56 5.56
Strong 100 94.44 38.88 83.33
TOTAL 100 100 100 100
Bauru School of Dentistry – University of São Paulo, São Paulo, 2002 to 2010.
Wilcoxon test; ρ = statistical significance level of 0.05. PO: podoplanin; EZ: ezrin; M: Membranous; C: Cytoplasmic.
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GTPase-RhoA [7]. This signaling pathway would promote
the rearrangement of the actin cytoskeleton and induce the
formation of filopodia-like projections, promoting the cellu-
lar movement [13]. So, in order to verify if podoplanin and
ezrin are co-localized in keratocystic odontogenic tumors,
we designed the present study.
Ezrin, an ERM protein family member, exerts primor-
dial functions related to the regulation of cellular move-
ment and structure by transducing signals between the
plasma membrane and the actin cytoskeleton [14]. Ezrin
is essential for many physiological cellular processes in-
cluding regulation of actin cytoskeleton, maintenance of
cell shape, adhesion, motility and modulation of signal
transduction pathways [14].
In head and neck squamous cell carcinomas, ezrin
was identified as a key molecule in tumor progression
and metastatic behavior of neoplastic cells and it has
been correlated with poor outcome [18-21], similarly
to podoplanin [22]. However, to the best of our know-
ledge, this is the first evidence that confirmed the immu-
noexpression of ezrin in benign keratocystic odontogenic
tumors.
The results presented here showed absence of mem-
branous ezrin in 55.56% of keratocystic odontogenic tu-
mors and, when present, this protein was mainly observed
in the membrane of the non-proliferative supra-basal
layers (Figure 2). From that we can hypothesize that ezrin
may be promoting the cellular adhesion, as similarly ob-
served in non-proliferating squamous cells of the normal
human oral mucosa [18,20,21].
Furthermore, most of the odontogenic tumors (83.33%)
showed strong cytoplasmic ezrin expression especially in
the basal layer of odontogenic epithelium. Interestingly, the
cytoplasmic ezrin reflects its activated [18,20,21] form and,
in oral cancer, this pattern of cytoplasmic ezrin has been
associated with invasive phenotype and more aggressive
behavior of malignant cells [18-21]. These findings suggest
that activated ezrin is necessary for the proliferation and/or
invasion of odontogenic cells once its cytoplasmic positiv-
ity was mainly found in the basal layers of keratocystic
odontogenic tumors, the region responsible for the tumor
growth.
The distribution of ezrin in odontogenic keratocystic
tumors was more heterogeneous than that of podoplanin
(Tables 1 and 2) and statistically significant differences
were observed among the localization of membranous
ezrin and cytoplasmic or membranous podoplanin
(Table 3). It was previously reported that ezrin is markedly
phosphorylated in the presence of podoplanin overexpres-
sion [13]. This interaction of podoplanin and ezrin is re-
sponsible for many of the effects on the cytoskeleton,
contributing to increased cell motility [13]. Additionally,
there is evidence that ERM function in organizing the cyto-
skeleton is mediated through its ability to bind actin and to
regulate GTPase-RhoA phosphorylation [13]. Interestingly,
the keratocystic odontogenic tumors presented strong
membranous podoplanin and cytoplasmic ezrin expres-
sion, which correspond to the activated forms of both pro-
teins. The podoplanin activated form (membranous) was
mostly found in the basal layer, indicating a co-localization
of active-ezrin and active-podoplanin in the highly active
areas of keratocystic odontogenic tumors. However, this
correlation was not statistically significant probably owing
to the low number of negative tumors (0 for membranous
podoplanin and 2 for cytoplasmic ezrin), which does not
permit to establishing an associative relationship (Table 4).
Conclusions
In summary, we first report that ezrin presents strong
membranous expression in the supra-basal layer and
strong cytoplasmic expression in the basal layer of kera-
tocystic odontogenic tumors. Thus, our investigation
suggests a role for ezrin and podoplanin in keratocystic
odontogenic tumors and their molecular interactions
need to be further explored in these kinds of tumors.
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